125 results about "Mg citrate" patented technology

A method for administering an antioxidant composition to humans according to their age and sex is disclosed wherein the method comprises administering to said humans a daily dose of a multiple antioxidant micronutrient composition comprising vitamin A (palmitate), beta carotene (from natural d. salina), vitamin C (calcium ascorbate), vitamin D-3 (cholecalciferol), natural source vitamin E including both d-alpha tocopheryl and d-alpha tocopheryl acid succinate, thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid (folacin), d-biotin, selenium (1-seleno methionine), chromium picolinate, zinc glycinate, calcium citrate, and magnesium citrate. For persons over the age of about 51, the composition preferably further comprises one or more of co-enzyme Q₁₀, N-acetyl cysteine, and alpha lipoic acid. Preferably, also, vitamin D is added for women over the age of about 36.

The invention provides an aqueous pharmaceutical composition for administration as an aerosol to the respiratory tract, nose or oropharyngeal region comprising (i) a macrolide having a poor taste and poor chemical stability in aqueous solution; (ii) at least one salt selected from the group consisting of sodium gluconate, sodium aspartate, sodium acetate, sodium lactate, sodium succinate, sodium maleate, magnesium gluconate, magnesium aspartate, magnesium citrate, magnesium acetate, magnesium lactate, magnesium succinate, and magnesium maleate; or mixtures thereof and (iii) a taste-masking agent different from said salt; wherein (a) the concentration of said macrolide in the composition is in the range of about 0.25 wt.-% to about 15 wt.-%; (b) the molar ratio of said macrolide:said salt is in the range from about 1:0.5 to about 1:100; (c) the pH of the composition is in the range of about 3 to 9; and (d) the osmolality of the composition is in the range of about 150 mOsmol/kg to about 1500 mOsmol/kg. The invention further provides a method of generating an aerosol, preferably by means of a nebuliser, which uses such an aqueous pharmaceutical composition. The macrolide may be used alone or in combination with other drugs. The composition is suitable to treat inflammatory disorders and/or infections of the respiratory tract. It has an improved taste and stability.

The invention provides a weathering crust illuviation-type rare-earth ore leaching agent and a method for extracting rare earths by using the same, particularly a leaching agent solution for weathering crust illuviation-type rare-earth ores. The active component is citrate, wherein the citrate is any one of ammonium citrate, sodium citrate, potassium citrate and magnesium citrate, or mixture of sodium citrate, potassium citrate and magnesium citrate. The method for extracting rare earths from weathering crust illuviation-type rare-earth ores comprises the following steps: leaching by using the citrate as the active component of the leaching agent to obtain a rare-earth leaching mother solution, removing impurities, and adding a precipitant to obtain a rare-earth enriched substance. In the weathering crust illuviation-type rare-earth extraction process, cation exchange interaction and anion (citrate ion) complex action exist, and the two actions can cooperate to enhance the rare-earth recovery rate and lower the concentration and consumption of the leaching agent.

The present invention provides novel compositions in the form of a powder, capsule, liquid or lozenge, and methods for administering said novel compositions to assist the body in its ability to maintain a reasonable homeostatic mechanism for compensating for chronic internal acidity. The composition may contain several active ingredients, such as potassium bicarbonate, citric acid, calcium citrate, magnesium citrate, glycine, and licorice. The composition may also contain other inactive excipients, such as hypoallergenic rice, flour, glycerine, tangerine oil and gelatin. Following oral administration, the composition is rapidly broken down and absorbed into the systemic circulation. Upon absorption, the individual components are able to assist the physiological acid-alkaline buffer systems, promote anti-anxiety effects, and decrease inflammation in the digestive system.

The invention discloses a staphylococcus cohnii selective medium and a preparation method thereof. The staphylococcus cohnii selective medium is characterized in that the 1000 ml of selective medium comprises the following components by weight: 15g of malt extract, 150ml of egg protein liquid, 5g of sodium chloride, 0.5g of magnesium citrate, 15g of agar, 8-12 mg of coetsoidin, 0.5g of acetovanillone and 0.2g of monopotassium phosphate, which are prepared to 1000 ml by adding distilled water. The optical preparation method comprises the following steps of: dissolving the malt extract, the egg protein liquid, sodium chloride, magnesium citrate, the agar, the coetsoidin, the acetovanillone, the monopotassium phosphate, L-cysteine and copper sulfate in lily decocted liquid; and uniformly mixing the components, metering the volume of the mixture, sterilizing, splitting and packaging the mixture. Compared with the prior art, the detection is reliable, and the separation rate of the staphylococcus lentus is high.

The anti-rust snow melting antifreezing agent has added antirust agent in the amount of 1-5 wt%. The antirust agent is citrate, including sodium citrate, magnesium citrate, calcium citrate, etc. and preferably sodium citrate. The anti-rust snow melting antifreezing agent can prevent metal part form rusting, and has no environmental pollution and toxin to animal and plant. It may be used for melting snow, defreezing and preventing freezing in road, airport, park, yard. The present invention is suitable for mechanical application and manual throwing.

The invention discloses efficient flocculant for improving the yield of stevioside. The efficient flocculant comprises, by weight, 30-40 parts of modified lignin, 25-35 parts of modified polymerization ferric sulfate, 3-6 parts of polyaluminum ferric chloride, 12-15 parts of polyaluminium sulfate, 4-8 parts of magnesium citrate, 12-20 parts of xanthan gum, 2-3 parts of activated carbon, 1-2 parts of kieselguhr and 2-4 parts of zeolite powder. The efficient flocculant for improving the yield of stevioside is fast in flocculoreaction, the production period is shortened, and particles of a flocculating constituent are large, and are easy to separate.

The invention relates to milk and a method for preparing the milk, in particular to baby liquid state milk added with mineral elements, which belongs to the technical field of milk products. The baby liquid state milk comprises protein, fat, sugar, vitamin, mineral elements and water. The mineral elements comprise Mg, Fe, Zn, Cu, Ca, I, and Mn; wherein, the Mg can be provided by the combination of one or a plurality of Mg preparations among magnesium sulfate, magnesium chloride and magnesium citrate; the Fe can be provided by the combination of one or a plurality of Fe preparations among gluconic acid ferrous iron, green copperas, ferrous lactate, ironic citrate and ferric pyrophosphate; the Zn can be provided by the combination of one or a plurality of Zn preparations among zinc sulfate, zinc gluconate, zinc lactate and zinc butter; the Cu can be provided by bluestone; the Ca can be provided by the combination of one or a plurality of Ca preparations among milk calcium, calcium citrate, calcium phosphate, calcium chloride, calcium carbonate and calcium lactate; the I can be provided by potassium iodide; and the Mn can be provided by manganese sulfate. The invention has the advantages that the selected combination is suitable for the liquid state milk.

A heart and pulmonry health micronutrient formulation is provided and the formulation comprises dietary antioxidants and endogenous antioxidants, and the formulation comprising dietary micronutrients and endogenous antioxidants, the dietary antioxidants are selected from a group consisting essentially of Vitamin A (Palmitate), Vitamin E, Vitamin C, Vitamin D₃ (Cholecalciferol), B Vitamins, Biotin, Pantothenic Acid (as D-Calcium Pantothenate), Calcium Citrate, Magnesium Citrate, Zinc Glycinate, Selenium (Seleno-L-Methionine), Chromium (as Chromium Picolinate), Mixed Carotenoids and mixtures thereof, and the endogenous antioxidants are selected from a group consisting essentially of N-Acetyl Cysteine (NAC), Coenzyme Q₁₀, R-alpha Lipoic Acid, Omega-3 fatty Acid, and L-Carnitine and mixtures thereof.

The invention provides a microbial improver for alkaline soil and a preparation method thereof. The microbial improver comprises, by weight parts, 30-40 parts of superphosphate, 20-30 parts of ammonium sulfate, 17-23 parts of potassium sulfate, 6-10 parts of compound microbial agents, 4-6 parts of lignin iron, 2-3 parts of magnesium citrate, 2-3 parts of manganese sulfate, 1-2 parts of wood vinegar and 0.4-0.6 part of zinc sulfate. The microbial improver for the alkaline soil can effectively overcome the imbalance of nutrients in the soil, improve soil properties, loosen the soil, improve thesoil fertility, and gradually improve the soil alkalization phenomenon.

Technical result of invention lies in practical realization of high-efficient remineralizing formulation using available and cheap components. Due to absence of fluorides it can be recommended to patients suffering from fluorosis, endocrine system diseases for the purpose of caries prophylaxis and non-carious affections. The formulation contains acceptable active and inert components. To the group of active components there belongs complex including sources of elements of magnesium, sodium, silica and potassium in quantity 1-11 wt. %. Here are ratios of atomic masses of elements of magnesium, sodium, silica, potassium, parts of active components complex, correspondingly, 21.3:9.3:1.67:1. As a source of magnesium element there is used magnesium chloride or magnesium glycerophosphate or magnesium citrate. As a source of sodium element there is used sodium chloride or sodium silicate. As a source of silica element there is used sodium metasilicate or potassium metasilicate. As a source of potassium element there is used potassium silicate.

The present invention relates to a magnesium citrate crystal production method, which comprises: injecting a magnesium salt slurry into a citric acid material liquid containing 1 kg of citric acid at a rate of 1-3.5 l/h, carrying out reaction crystallization, stopping the injecting when the pH value of the citric acid material liquid is 5.5-7.8, and maintaining for 10-30 min to obtain a crystal slurry. The invention further relates to a magnesium citrate crystal prepared through the preparation method. According to the present invention, the content of the magnesium citrate crystal prepared by using the method of the present invention is up to 99.2-99.9 wt%.

The invention discloses a magnesium binding agent for cement-free castable and a preparation method thereof. The preparation method comprises the following steps: baking a magnesium raw material containing crystal water at a high temperature to remove the crystal water, and then grinding and sieving to obtain the magnesium binding agent, wherein the magnesium raw material can be any one of magnesium citrate, magnesium oxalate, magnesium gluconate and the like, the high temperature is 100-400 DEG C, and the baking time is 1-200 hours. The magnesium binding agent can form a net-shaped structureand has coagulation performance when being added with water and stirred, a refractory castable prepared from the magnesium binding agent has excellent normal-temperature mechanical performance, and spinel generated in situ at high temperature can improve the erosion resistance and thermal shock resistance of the castable; the binding agent has the advantages of no environmental pollution, simple production process, low production energy consumption and the like, is wide in application range, and is suitable for high-alumina, corundum, silicon carbide and other cement-free castables.

The invention discloses a novel bean curd coagulant, which is prepared by 1 part of sodium malate, 2 parts of calcium malate, 1 part of sodium succinate, 1 part of calcium acetate, 1 part of sodium tartrate, 3 parts of calcium lactate and 2 parts of magnesium citrate by weight. The novel bean curd coagulant is the organic acids coagulant which majors in calcium and magnesium organic acid salt so as to accelerate solidification of the bean curd; and bean curds prepared by the novel bean curd coagulant is exquisite smooth and has better taste.

The invention provides a compound microorganism fertilizer with a high nutrition content, and a preparation method thereof, and relates to the technical field of plant fertilizer. The compound microorganism fertilizer with the high nutrition content is prepared from the following raw materials: saccharomycetes, acetic bacteria, yield improvement bacteria, potassium humate, bacillus licheniformis,trichoderma koningii, bacillus megatherium, furfural residue, waste sugar solution, wheat bran, amino acid, microelement, nitramine phosphorus, urea sulfate, calcium magnesium phosphate, monopotassiumphosphate, potassium fulvic acid and magnesium citrate. According to the compound microorganism fertilizer with the high nutrition content, no environment pollution is caused, crop growth can be accelerated, crop quality is improved, the biological activity of soil can be improved, the substance circulation of a soil ecological system is accelerated, harmful cultures in soil can be effectively prevented from breeding, organic nutriments are provided, the physical and chemical structure of the soil is improved, and the contents of nutrition substances in the soil are improved.

The present invention discloses pharmaceutical/nutritional compositions and methods for alleviating symptoms associated with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). The pharmaceutical/nutritional compositions include at least 2% (w/w) phosphatidyl-L-serine, or salts thereof, out of a total effective composition, as a first effective ingredient; and a suitable amount of at least one bio-available form of magnesium as a second effective ingredient. Preferably, the bio-available form of magnesium is magnesium oxide, magnesium citrate, magnesium hydroxide, magnesium stearate, or a magnesium salt of the phosphatidyl-L-serine. Preferably, the composition further includes a pharmaceutical or nutritional excipient. Preferably, the total effective composition is administrable in a multi-part regimen. Preferably, the total effective composition is administrable by intravenous or oral delivery. Preferably, the pharmaceutical/nutritional composition further includes at least 2% (w/w) phosphatidic acid, or salts thereof, out of the total effective composition, as a first effective ingredient.

A radioactive protection micronutrient formulation system is provided and the system comprises: a formulation consisting essentially of antioxidants, the antioxidants are selected from the group consisting essentially of vitamin C, vitamin E, N-acetyl cysteine, natural mixed carotenoids, and alpha-lipoic acid, vitamin A (palmitate), vitamin D-3 (cholecalciferol), thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid, D-Biotin, selenium (1-seleno-methionine), chromium picolinate, zinc glycinate, calcium citrate and magnesium citrate and mixtures thereof; and plus a booster formulation selected from a group consisting essentially of vitamin C, d-alpha tocopheryl acid succinate, alpha tocopherol, N-acetyl cysteine, natural mixed carotenoids and alpha lipoic acid, the formulation is designed to reduce the risk in humans exposed to doses of ionizing radiation of becoming subjected to at least one condition selected from the group consisting essentially of radiation-induced acute leukemia, breast cancer, thyroid cancer and other somatic and heritable mutations.

The invention is directed at the formulation of Mucuna pruiens, N Acetyl L Cysteine and Magnesium Citrate. This formulation augments dopamine in the striatal area of the human brain and stabilizes membranes by restoring normal neurotransmitter levels and decreasing endogenous catecholamines. These effects are beneficial in the short and long term treatment of addictive disease and addiction to chemical substances and addictive behaviors.

The invention provides an organic matter removal compound flocculating agent which comprises, by weight, 30-50 parts of polymerization ferric chloride-organic compound flocculating agents, 10-20 partsof modified fly ash polymerized iron sulfate, 10-20 parts of magnesium citrate, 8-16 parts of polysilicic acid flocculating agents, 4-8 parts of agglomeration agents and 2-4 parts of xanthan gum. Thepolymerization ferric chloride-organic compound flocculating agents are mainly prepared from ferric trichloride, aluminum chloride and carboxylated chitosan. The flocculating agent is high in flocculating velocity and adsorption capacity and high water quality applicability, a molecular elongation layer is large in water, ion dispersion is high, negative ion and positive ion matters are effectively removed, the flocculating agent has coagulation sedimentation properties, and effluent quality and effluent stability of a sedimentation tank can be remarkably improved.